Acrux Limited (ARUXF)
USD 0.04
(0.0%)
USD 0.04
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -1.45 Million AUD | 119.57% |
| 2023 | -3.87 Million AUD | -3.36% |
| 2022 | -3.75 Million AUD | 71.21% |
| 2021 | -13.03 Million AUD | -91.57% |
| 2020 | -6.8 Million AUD | 62.51% |
| 2019 | -18.15 Million AUD | 36.24% |
| 2018 | -28.47 Million AUD | 16.2% |
| 2017 | -33.97 Million AUD | -15.72% |
| 2016 | -29.36 Million AUD | -27.28% |
| 2015 | -23.06 Million AUD | 10.5% |
| 2014 | -25.77 Million AUD | -12.85% |
| 2013 | -22.84 Million AUD | 23.91% |
| 2012 | -30.01 Million AUD | 9.48% |
| 2011 | -33.15 Million AUD | 43.42% |
| 2010 | -58.6 Million AUD | -297.73% |
| 2009 | -14.73 Million AUD | 57.12% |
| 2008 | -34.36 Million AUD | -99.49% |
| 2007 | -17.22 Million AUD | 12.73% |
| 2006 | -19.73 Million AUD | 29.67% |
| 2005 | -28.06 Million AUD | -327.63% |
| 2004 | -6.56 Million AUD | 39.4% |
| 2003 | -10.83 Million AUD | 39.32% |
| 2002 | -17.84 Million AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 FY | 759 Thousand AUD | 119.57% |
| 2024 Q2 | -2.3 Million AUD | 40.55% |
| 2024 Q4 | -1.45 Million AUD | 132.91% |
| 2023 Q2 | -2.36 Million AUD | 36.98% |
| 2023 Q4 | -3.87 Million AUD | -64.02% |
| 2023 FY | -3.87 Million AUD | -3.36% |
| 2022 FY | -3.75 Million AUD | 71.21% |
| 2022 Q2 | -8.44 Million AUD | 35.21% |
| 2022 Q4 | -3.75 Million AUD | 55.56% |
| 2021 Q2 | -9.14 Million AUD | -34.34% |
| 2021 FY | -13.03 Million AUD | -91.57% |
| 2021 Q4 | -13.03 Million AUD | -42.59% |
| 2020 Q2 | -11.98 Million AUD | 33.96% |
| 2020 Q4 | -6.8 Million AUD | 43.23% |
| 2020 FY | -6.8 Million AUD | 62.51% |
| 2019 Q2 | -22.22 Million AUD | 21.94% |
| 2019 Q4 | -18.15 Million AUD | 18.32% |
| 2019 FY | -18.15 Million AUD | 36.24% |
| 2018 Q2 | -32.36 Million AUD | 4.74% |
| 2018 FY | -28.47 Million AUD | 16.2% |
| 2018 Q4 | -28.47 Million AUD | 12.03% |
| 2017 Q4 | -33.97 Million AUD | -7.11% |
| 2017 FY | -33.97 Million AUD | -15.72% |
| 2017 Q2 | -31.71 Million AUD | -8.03% |
| 2016 Q4 | -29.36 Million AUD | -36.31% |
| 2016 FY | -29.36 Million AUD | -27.28% |
| 2016 Q2 | -21.53 Million AUD | 6.63% |
| 2015 Q4 | -23.06 Million AUD | -46.07% |
| 2015 FY | -23.06 Million AUD | 10.5% |
| 2015 Q2 | -15.79 Million AUD | 38.73% |
| 2014 Q2 | -17.48 Million AUD | 23.45% |
| 2014 FY | -25.77 Million AUD | -12.85% |
| 2014 Q4 | -25.77 Million AUD | -47.42% |
| 2013 Q2 | -19.04 Million AUD | 36.57% |
| 2013 FY | -22.84 Million AUD | 23.91% |
| 2013 Q4 | -22.84 Million AUD | -19.95% |
| 2012 FY | -30.01 Million AUD | 9.48% |
| 2012 Q4 | -30.01 Million AUD | 0.0% |
| 2011 FY | -33.15 Million AUD | 43.42% |
| 2011 Q4 | -33.15 Million AUD | 0.0% |
| 2010 Q4 | -58.6 Million AUD | 0.0% |
| 2010 FY | -58.6 Million AUD | -297.73% |
| 2009 Q4 | -14.73 Million AUD | 0.0% |
| 2009 FY | -14.73 Million AUD | 57.12% |
| 2008 Q4 | -34.36 Million AUD | 0.0% |
| 2008 FY | -34.36 Million AUD | -99.49% |
| 2007 FY | -17.22 Million AUD | 12.73% |
| 2007 Q4 | -17.22 Million AUD | 0.0% |
| 2006 FY | -19.73 Million AUD | 29.67% |
| 2006 Q4 | -19.73 Million AUD | 0.0% |
| 2005 Q4 | -28.06 Million AUD | 0.0% |
| 2005 FY | -28.06 Million AUD | -327.63% |
| 2004 FY | -6.56 Million AUD | 39.4% |
| 2004 Q4 | -6.56 Million AUD | 0.0% |
| 2003 FY | -10.83 Million AUD | 39.32% |
| 2002 FY | -17.84 Million AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -116.613% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 220.11% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 244.684% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 103.407% |
| GB Sciences, Inc. | 1.74 Million USD | 183.442% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 83.507% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -15630.972% |
| Skye Bioscience, Inc. | -5.72 Million USD | 74.517% |
| Zenith Capital Corp. | 10.06 Thousand USD | 14587.281% |
| Agentix Corp. | 37.63 Thousand USD | 3974.465% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 125.813% |
| Biomind Labs Inc. | 711.4 Thousand USD | 304.947% |
| ContraFect Corporation | -6.02 Million USD | 75.805% |
| CSL Limited | 10.52 Billion USD | 100.014% |
| CytoDyn Inc. | 20.26 Million USD | 107.196% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 505.327% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 334.268% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 103.357% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -7044.257% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 257.25% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 329.546% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 76.874% |
| SQZ Biotechnologies Company | -36.23 Million USD | 95.977% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 269.487% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 109.25% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 165.024% |
| Mesoblast Limited | 55.85 Million USD | 102.61% |
| Marizyme, Inc. | 18.56 Million USD | 107.852% |
| Genus plc | 190.6 Million USD | 100.765% |
| Pharming Group N.V. | 109.8 Million USD | 101.328% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 314.412% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 226.187% |
| IMV Inc. | 7.67 Million USD | 119.008% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 126.5% |
| MultiCell Technologies, Inc. | 90.04 USD | 1619380.32% |
| ONE Bio Corp. | 9.04 Million USD | 116.128% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 111.262% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 104.772% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 172.922% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 111.385% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 1142.889% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 7438.803% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -693.305% |
| Enzolytics Inc. | 981.65 Thousand USD | 248.525% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 99.928% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 96.899% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 120.62% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.863% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 135.405% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 462.823% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 161.106% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 986.274% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -7859.384% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 165.211% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 1182.896% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -98.644% |
| Helix BioMedix, Inc. | -2.57 Million USD | 43.269% |
| EV Biologics, Inc. | 1.36 Million USD | 206.581% |
| Q BioMed Inc. | 4.06 Million USD | 135.911% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 107.191% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 102.408% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | 132.603% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 166.213% |
| HST Global, Inc. | 96.79 Thousand USD | 1606.307% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -111197.71% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 807.022% |
| Halberd Corporation | 144.72 Thousand USD | 1107.456% |
| Resverlogix Corp. | 6.45 Million USD | 122.601% |
| Cell Source, Inc. | 9.23 Million USD | 115.793% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 153.828% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | -5.9 Million USD | 75.302% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 827.429% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | 2.17 Million USD | 166.928% |
| Kadimastem Ltd | -253.1 Thousand USD | -476.052% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 1172.146% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 824.458% |
| LadRx Corporation | -2.03 Million USD | 28.405% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 329.546% |
| Affymax, Inc. | -5.59 Million USD | 73.95% |
| Itoco Inc. | 228.3 Thousand USD | 738.619% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 129.413% |
| Mobile Lads Corp. | 484.23 Thousand USD | 401.095% |
| International Stem Cell Corporation | 2.59 Million USD | 156.293% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | 1.89 Million USD | 176.781% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -225247.759% |
| Qrons Inc. | 351.42 Thousand USD | 514.88% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 118.92% |
| SYBLEU INC | 473.71 Thousand USD | 407.781% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -484.088% |
| Rebus Holdings, Inc. | 305 Thousand USD | 578.033% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 132.712% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 2436.052% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 166.853% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 142.458% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 117.047% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 288.712% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -16.64% |
| Neutra Corp. | 52.18 Thousand USD | 2893.799% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 41.422% |
| PureTech Health plc | -167.19 Million USD | 99.128% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -495.326% |
| IXICO plc | -4.44 Million USD | 67.196% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 111.03% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 102.658% |
| CSL Limited | 10.52 Billion USD | 100.014% |
| Cellectis S.A. | -43.81 Million USD | 96.673% |